New hope for tough lung cancer: combo therapy enters human trials

NCT ID NCT07407933

Recruiting now Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Feb 13, 2026 · Last updated May 11, 2026 · Updated 8 times

Summary

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find the safest and most effective dose. About 118 adults who have not had prior treatment for this cancer will take part. The treatment continues until the cancer worsens or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THORACIC NEOPLASMS, LUNG DISEASES, SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 1001
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20057, United States

Contact
Site 1002
RECRUITING

Fairfax, Virginia, 22031, United States

Contact
Site 1005
RECRUITING

Houston, Texas, 77030, United States

Contact
Site 2201
RECRUITING

London, W12 0HS, United Kingdom

Contact

Conditions

Explore the condition pages connected to this study.

THORACIC NEOPLASMS, LUNG DISEASES, SMALL CELL LUNG CARCINOMA